TY - JOUR
T1 - The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group, Report 2
T2 - Real-world data for the impact of cataract surgery on diabetic macular oedema
AU - Denniston, Alastair K.
AU - Chakravarthy, Usha
AU - Zhu, Haogang
AU - Lee, Aaron Y.
AU - Crabb, David P.
AU - Tufail, Adnan
AU - Bailey, Clare
AU - Akerele, Toks
AU - Al-Husainy, Sahar
AU - Brand, Christopher
AU - Downey, Louise
AU - Fitt, Alan
AU - Khan, Rehna
AU - Kumar, Vineeth
AU - Lobo, Aires
AU - Mahmood, Sajjad
AU - Mandal, Kaveri
AU - Mckibbin, Martin
AU - Menon, Geeta
AU - Natha, Salim
AU - Ong, Jong Min
AU - Tsaloumas, Marie D.
AU - Varma, Atul
AU - Wilkinson, Elizabeth
AU - Johnston, Robert L.
AU - Egan, Catherine A.
N1 - Publisher Copyright:
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Aim To assess the rate of 'treatment-requiring diabetic macular oedema (DMO)' in eyes for the twoyears before and after cataract surgery. Methods Multicentre national diabetic retinopathy (DR) database study with anonymised data extraction across 19 centres from an electronic medical record system. Inclusion criteria: Eyes undergoing cataract surgery in patients with diabetes with no history of DMO prior to study start. The minimum dataset included: Age, visual acuity (all time-points), injection episodes, timing of cataract surgery and ETDRS grading of retinopathy and maculopathy. Main outcome measure: Rate of developing first episode of treatment-requiring DMO in relation to timing of cataract surgery in the same eye. Results 4850 eyes met the inclusion criteria. The rate of developing treatment-requiring DMO in this cohort was 2.9% in the year prior to surgery versus 5.3% in the year after surgery (p<0.01). The risk of 'treatment-requiring DMO' increased sharply after surgery, peaking in the 3-6 months' period (annualised rates of 5.2%, 6.8%, 5.6% and 4.0% for the 0-3, 3-6, 6-9 and 9-12 months' post-operative time periods respectively). Risk was associated with pre-operative grade of retinopathy: Risk of DMO in the first year post-operatively being 1.0% (no DR pre-operatively), 5.4% (mild non-proliferative diabetic retinopathy; NPDR), 10.0% (moderate NPDR), 13.1% (severe NPDR) and 4.9% (PDR) (p<0.01). Conclusions This large real-world study demonstrates that the rate of developing treatment-requiring DMO increases sharply in the year after cataract surgery for all grades of retinopathy, peaking in the 3-6 months' postoperative period. Patients with moderate and severe NPDR are at particularly high risk.
AB - Aim To assess the rate of 'treatment-requiring diabetic macular oedema (DMO)' in eyes for the twoyears before and after cataract surgery. Methods Multicentre national diabetic retinopathy (DR) database study with anonymised data extraction across 19 centres from an electronic medical record system. Inclusion criteria: Eyes undergoing cataract surgery in patients with diabetes with no history of DMO prior to study start. The minimum dataset included: Age, visual acuity (all time-points), injection episodes, timing of cataract surgery and ETDRS grading of retinopathy and maculopathy. Main outcome measure: Rate of developing first episode of treatment-requiring DMO in relation to timing of cataract surgery in the same eye. Results 4850 eyes met the inclusion criteria. The rate of developing treatment-requiring DMO in this cohort was 2.9% in the year prior to surgery versus 5.3% in the year after surgery (p<0.01). The risk of 'treatment-requiring DMO' increased sharply after surgery, peaking in the 3-6 months' period (annualised rates of 5.2%, 6.8%, 5.6% and 4.0% for the 0-3, 3-6, 6-9 and 9-12 months' post-operative time periods respectively). Risk was associated with pre-operative grade of retinopathy: Risk of DMO in the first year post-operatively being 1.0% (no DR pre-operatively), 5.4% (mild non-proliferative diabetic retinopathy; NPDR), 10.0% (moderate NPDR), 13.1% (severe NPDR) and 4.9% (PDR) (p<0.01). Conclusions This large real-world study demonstrates that the rate of developing treatment-requiring DMO increases sharply in the year after cataract surgery for all grades of retinopathy, peaking in the 3-6 months' postoperative period. Patients with moderate and severe NPDR are at particularly high risk.
KW - Cataract
KW - Diabetic macular oedema
KW - Diabetic retinopathy
KW - Electronic medical record
KW - Intravitreal therapy
UR - https://www.scopus.com/pages/publications/85025810053
U2 - 10.1136/bjophthalmol-2016-309838
DO - 10.1136/bjophthalmol-2016-309838
M3 - Article
C2 - 28487377
AN - SCOPUS:85025810053
SN - 0007-1161
VL - 101
SP - 1673
EP - 1678
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 12
ER -